Shots:

• The approval is based on P-III BEACON CRC trial evaluating Braftovi (300mg- qd) + Erbitux vs irinotecan + Erbitux or Folfiri + Erbitux in a ratio (1:1:1) in 441 patients with previously treated mCRC with a BRAF V600E mutation after prior therapy
• Erbitux + Braftovi showed an improved OS; m-OS (8.4 vs 5.4mos.); ORR (20% vs 2%); CR (5% vs 2%); PR (15% vs 2%) and m-PFS (4.2 vs 1.5mos.)
• Erbitux is the 1^st anti-EGFR antibody approved in combination with encorafenib for adults with previously treated mCRC with a BRAF V600E mutation. On April 8- 2020- the FDA has approved Pfizer's encorafenib for the same indication

  | Ref: PR Newswire | Image: Forbes